SunTrust Banks Equities Analysts Lift Earnings Estimates for Spark Therapeutics Inc (ONCE)

Spark Therapeutics Inc (NASDAQ:ONCE) – Equities researchers at SunTrust Banks lifted their FY2018 earnings per share estimates for shares of Spark Therapeutics in a research report issued to clients and investors on Wednesday. SunTrust Banks analyst E. Nash now anticipates that the biotechnology company will post earnings of ($5.38) per share for the year, up from their prior estimate of ($5.60). SunTrust Banks has a “Buy” rating and a $113.00 price objective on the stock. SunTrust Banks also issued estimates for Spark Therapeutics’ Q4 2018 earnings at ($1.09) EPS, FY2019 earnings at ($1.97) EPS, FY2020 earnings at $0.80 EPS and FY2021 earnings at $2.54 EPS.

ONCE has been the subject of several other reports. Cantor Fitzgerald dropped their price target on Spark Therapeutics from $105.00 to $94.00 and set a “buy” rating for the company in a report on Friday, October 13th. Cowen reissued a “buy” rating and set a $95.00 price target on shares of Spark Therapeutics in a report on Tuesday, October 10th. Raymond James Financial reissued a “buy” rating and set a $75.00 price target on shares of Spark Therapeutics in a report on Thursday, December 7th. Barclays lifted their price target on Spark Therapeutics from $104.00 to $107.00 and gave the stock an “overweight” rating in a report on Friday, October 13th. Finally, Chardan Capital reissued a “buy” rating and set a $100.00 price target on shares of Spark Therapeutics in a report on Friday, October 13th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $76.03.

Spark Therapeutics (ONCE) traded up $0.89 during trading hours on Monday, reaching $51.49. The company had a trading volume of 1,031,836 shares, compared to its average volume of 1,127,383. The firm has a market cap of $1,910.00 and a PE ratio of -7.15. Spark Therapeutics has a 1-year low of $41.06 and a 1-year high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). The firm had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The business’s revenue for the quarter was up 45.8% on a year-over-year basis. During the same period in the previous year, the business posted ($1.07) earnings per share.

In other news, insider Barge Joseph La sold 5,500 shares of Spark Therapeutics stock in a transaction on Monday, November 13th. The stock was sold at an average price of $71.44, for a total value of $392,920.00. Following the transaction, the insider now owns 8,146 shares in the company, valued at approximately $581,950.24. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Daniel Faga sold 6,000 shares of Spark Therapeutics stock in a transaction on Friday, October 20th. The shares were sold at an average price of $79.95, for a total value of $479,700.00. Following the completion of the transaction, the insider now owns 6,000 shares in the company, valued at approximately $479,700. The disclosure for this sale can be found here. In the last quarter, insiders sold 62,309 shares of company stock worth $4,621,085. Corporate insiders own 7.30% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. increased its stake in shares of Spark Therapeutics by 15.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock valued at $164,986,000 after purchasing an additional 241,016 shares during the last quarter. Ameriprise Financial Inc. grew its position in Spark Therapeutics by 6.0% during the 3rd quarter. Ameriprise Financial Inc. now owns 207,360 shares of the biotechnology company’s stock worth $18,489,000 after acquiring an additional 11,785 shares during the last quarter. BlackRock Inc. grew its position in Spark Therapeutics by 11.6% during the 2nd quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock worth $122,689,000 after acquiring an additional 213,520 shares during the last quarter. Amundi Pioneer Asset Management Inc. bought a new stake in Spark Therapeutics during the 3rd quarter worth $5,286,000. Finally, Alyeska Investment Group L.P. bought a new stake in Spark Therapeutics during the 3rd quarter worth $13,519,000. Institutional investors own 94.91% of the company’s stock.

TRADEMARK VIOLATION WARNING: “SunTrust Banks Equities Analysts Lift Earnings Estimates for Spark Therapeutics Inc (ONCE)” was first posted by Markets Daily and is owned by of Markets Daily. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.themarketsdaily.com/2018/01/10/suntrust-banks-equities-analysts-lift-earnings-estimates-for-spark-therapeutics-inc-once.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply